CIK 0001398733
- Non-accelerated filer
- Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208623253
- Phone
- +1 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $297,289
- in 4 filings, $297K under 10b5-1 plans
Net −$197,958. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-12 | Davis Matthew W. Chief Development Officer | Sale 10b5-1 | −7,197 | $3.55 | $26K | 87,500 |
| 2026-11-10 | Davis Matthew W. Chief Development Officer | Shares withheld for taxes | −5,303 | $3.52 | $19K | 94,697 |
| 2026-03-09 | Davis Matthew W. Chief Development Officer | Grant or award | +50,000 | 100,000 | ||
| 2026-03-09 | Davis Matthew W. Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-11-10 | Davis Matthew W. Chief Development Officer | Grant or award | +50,000 | 50,000 | ||
| 2025-11-10 | Davis Matthew W. Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | 50,000 |
Page 1 of 1 · 6 trades